{"id":294538,"date":"2025-06-30T00:00:00","date_gmt":"2025-06-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042080-medtech-neurovascular-devices-market-insights-europe\/"},"modified":"2026-03-31T10:09:38","modified_gmt":"2026-03-31T10:09:38","slug":"47042546-medtech-neurovascular-devices-market-insights-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042546-medtech-neurovascular-devices-market-insights-europe\/","title":{"rendered":"Neurovascular Devices &#8211; Market Insights &#8211; Europe"},"content":{"rendered":"<p>The European neurovascular device market is poised to experience <span>strong growth <\/span>through 2034. This growth will be driven by the introduction of newly developed technologies, increasing adoption of innovative devices backed by strong clinical evidence, and a rise in neurovascular procedure volumes due to Europe\u2019s growing elderly population\u2014alongside the urgent and complex nature of these interventions.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for neurovascular devices in Europe from 2019 through 2034.<\/p>\n<p class=\"question-statement\"><strong>Adoption of neurovascular thrombectomy devices is rising in Europe due to clinical benefits, innovation, and supportive healthcare policies.<\/strong><\/p>\n<p>How much market growth is expected in the neurovascular\u00a0thrombectomy device\u00a0segment in the European countries?<\/p>\n<p>How will the launch of new technologies in the neurovascular thrombectomy device market influence adoption of thrombectomy for <abbr title=\"Acute Ischemic Stroke\">AIS<\/abbr>?<\/p>\n<p>What role do ongoing clinical trials play in expanding the use of neurovascular thrombectomy devices?<\/p>\n<p><strong>Companies are releasing new devices and better versions of existing ones to stay ahead in the growing market.<\/strong><\/p>\n<p class=\"question-statement\">How are established players leveraging next-generation product launches to defend market share and differentiate from emerging competitors?<\/p>\n<p class=\"question-statement\">Which new companies are planning to enter the neurovascular thrombectomy device market in Europe?<\/p>\n<p>What difficulties might these new companies face? Will they be able to take a large share of the market from current players?<\/p>\n<p><!--{C}%3C!%2D%2DStartFragment%20%2D%2D%3E-->What design improvements or clinical features are driving the appeal of upgraded neurovascular devices?<\/p>\n<p><strong>Embolization represents an emerging treatment for chronic subdural hematomas.<\/strong><\/p>\n<p>What new embolization products and companies are entering this market segment?<\/p>\n<p>Which companies are likely to gain more market share in this space and how?<\/p>\n<p>How strongly are embolization products being adopted for this indication? What is the future adoption outlook?<\/p>\n<p>Which factors affect the decision to choose this emerging treatment?<\/p>\n<p><!--EndFragment --><\/p>\n<p class=\"question-statement\">How will the use of embolization procedures for treating chronic subdural hematoma differ across European countries?<\/p>\n<p class=\"question-statement\"><strong>Flow-diverting devices are contributing to growth in the neurovascular embolization device market.<\/strong><\/p>\n<p><!--StartFragment -->How is innovation in flow-diverting device design fueling broader market acceptance and global procedural growth?<!--EndFragment --><\/p>\n<p>What strategies are companies using to stay ahead in the flow-diverting device market?<\/p>\n<p>What effect will new companies and products have on the European neurovascular device market?<!--EndFragment --><\/p>\n","protected":false},"template":"","class_list":["post-294538","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-cardiovascular","medtech-geography-europe","medtech-date-2294"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294538\/revisions"}],"predecessor-version":[{"id":486783,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294538\/revisions\/486783"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}